Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 5, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 23, 2007.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital movements.
- Shares Repurchased: 1,650,000 ordinary shares.
- Repurchase Price: 1,221.14 pence per share.
- Treasury Shares Held: 476,989,158 shares (representing 8.56% of total voting rights).
- Shares in Issue: 5,548,221,549 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the increase in the company's Treasury shareholding following the November 5 transaction. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,548,221,549) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (476,989,158) and its impact on total voting rights (8.56%).
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for revenue and earnings data.